SCHEMBL4710346

SCHEMBL4710346

Cc1ccc(O)c(/C=C\c2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 6/20 0.51
ALDH1A1 P00352 5/20 0.51
HPGD P15428 4/20 0.51
KDM4E B2RXH2 3/20 0.51
NPC1 O15118 2/20 0.51
GRM5 P41594 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
MEN1 O00255 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
PKM P14618 2/20 0.51
NFKB1 P19838 2/20 0.51
CYP2C19 P33261 2/20 0.51
THPO P40225 2/20 0.51
KMT2A Q03164 2/20 0.51
HIF1A Q16665 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712775 1.00 GRM4 (0.51) GRM4ALDH1A1HPGDKDM4ENPC1
SCHEMBL4710348 1.00 GRM4 (0.51) GRM4ALDH1A1HPGDKDM4ENPC1
SCHEMBL4710561 0.83 ALOX5 (0.49) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4710560 0.83 ALOX5 (0.49) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4711845 0.81 CHAT (0.45) ALDH1A1HPGDKDM4ESMN1; SMN2MEN1
SCHEMBL4711844 0.81 CHAT (0.45) ALDH1A1HPGDKDM4ESMN1; SMN2MEN1
SCHEMBL4714569 0.81 PTGS1 (0.58) GRM4ALDH1A1HPGDKDM4ENPC1
SCHEMBL4714571 0.81 PTGS1 (0.58) GRM4ALDH1A1HPGDKDM4ENPC1
SCHEMBL18149445 0.79 GRM4 (0.53) GRM4ALDH1A1HPGDKDM4ENPC1
SCHEMBL18149448 0.79 GRM4 (0.53) GRM4ALDH1A1HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-A2 PYRIDINE DERIVATIVES Novartis AG (CH) 2000-05-10 EP claimed
WO-1999002497-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 1999-01-21 WO claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed